Copyright Reports & Markets. All rights reserved.

Global Late-Stage Oncology Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Late-Stage Oncology Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Chemotherapy
    • 1.3.3 Targeted Therapy
    • 1.3.4 Immunotherapy
    • 1.3.5 Hormonal Therapy
    • 1.3.6 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Late-Stage Oncology Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Blood Cancer
    • 1.4.3 Breast Cancer
    • 1.4.4 Gastrointestinal Cancer
    • 1.4.5 Prostate Cancer
    • 1.4.6 Respiratory or Lung Cancer
    • 1.4.7 Other
  • 1.5 Global Late-Stage Oncology Drug Market Size & Forecast
    • 1.5.1 Global Late-Stage Oncology Drug Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Late-Stage Oncology Drug Sales Quantity (2019-2030)
    • 1.5.3 Global Late-Stage Oncology Drug Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Late-Stage Oncology Drug Product and Services
    • 2.1.4 Roche Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Merck & Co
    • 2.2.1 Merck & Co Details
    • 2.2.2 Merck & Co Major Business
    • 2.2.3 Merck & Co Late-Stage Oncology Drug Product and Services
    • 2.2.4 Merck & Co Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Merck & Co Recent Developments/Updates
  • 2.3 Bristol Myers
    • 2.3.1 Bristol Myers Details
    • 2.3.2 Bristol Myers Major Business
    • 2.3.3 Bristol Myers Late-Stage Oncology Drug Product and Services
    • 2.3.4 Bristol Myers Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Bristol Myers Recent Developments/Updates
  • 2.4 Pfizer
    • 2.4.1 Pfizer Details
    • 2.4.2 Pfizer Major Business
    • 2.4.3 Pfizer Late-Stage Oncology Drug Product and Services
    • 2.4.4 Pfizer Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Pfizer Recent Developments/Updates
  • 2.5 Novartis
    • 2.5.1 Novartis Details
    • 2.5.2 Novartis Major Business
    • 2.5.3 Novartis Late-Stage Oncology Drug Product and Services
    • 2.5.4 Novartis Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Novartis Recent Developments/Updates
  • 2.6 AstraZeneca
    • 2.6.1 AstraZeneca Details
    • 2.6.2 AstraZeneca Major Business
    • 2.6.3 AstraZeneca Late-Stage Oncology Drug Product and Services
    • 2.6.4 AstraZeneca Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 AstraZeneca Recent Developments/Updates
  • 2.7 Johnson & Johnson
    • 2.7.1 Johnson & Johnson Details
    • 2.7.2 Johnson & Johnson Major Business
    • 2.7.3 Johnson & Johnson Late-Stage Oncology Drug Product and Services
    • 2.7.4 Johnson & Johnson Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Johnson & Johnson Recent Developments/Updates
  • 2.8 Eli Lilly and Company
    • 2.8.1 Eli Lilly and Company Details
    • 2.8.2 Eli Lilly and Company Major Business
    • 2.8.3 Eli Lilly and Company Late-Stage Oncology Drug Product and Services
    • 2.8.4 Eli Lilly and Company Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Eli Lilly and Company Recent Developments/Updates
  • 2.9 Sanofi
    • 2.9.1 Sanofi Details
    • 2.9.2 Sanofi Major Business
    • 2.9.3 Sanofi Late-Stage Oncology Drug Product and Services
    • 2.9.4 Sanofi Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Sanofi Recent Developments/Updates
  • 2.10 AbbVie
    • 2.10.1 AbbVie Details
    • 2.10.2 AbbVie Major Business
    • 2.10.3 AbbVie Late-Stage Oncology Drug Product and Services
    • 2.10.4 AbbVie Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 AbbVie Recent Developments/Updates
  • 2.11 GSK
    • 2.11.1 GSK Details
    • 2.11.2 GSK Major Business
    • 2.11.3 GSK Late-Stage Oncology Drug Product and Services
    • 2.11.4 GSK Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 GSK Recent Developments/Updates
  • 2.12 Amgen
    • 2.12.1 Amgen Details
    • 2.12.2 Amgen Major Business
    • 2.12.3 Amgen Late-Stage Oncology Drug Product and Services
    • 2.12.4 Amgen Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Amgen Recent Developments/Updates
  • 2.13 Genentech
    • 2.13.1 Genentech Details
    • 2.13.2 Genentech Major Business
    • 2.13.3 Genentech Late-Stage Oncology Drug Product and Services
    • 2.13.4 Genentech Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Genentech Recent Developments/Updates
  • 2.14 Daiichi Sankyo Group
    • 2.14.1 Daiichi Sankyo Group Details
    • 2.14.2 Daiichi Sankyo Group Major Business
    • 2.14.3 Daiichi Sankyo Group Late-Stage Oncology Drug Product and Services
    • 2.14.4 Daiichi Sankyo Group Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Daiichi Sankyo Group Recent Developments/Updates
  • 2.15 Aveo Oncology
    • 2.15.1 Aveo Oncology Details
    • 2.15.2 Aveo Oncology Major Business
    • 2.15.3 Aveo Oncology Late-Stage Oncology Drug Product and Services
    • 2.15.4 Aveo Oncology Late-Stage Oncology Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.15.5 Aveo Oncology Recent Developments/Updates

3 Competitive Environment: Late-Stage Oncology Drug by Manufacturer

  • 3.1 Global Late-Stage Oncology Drug Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Late-Stage Oncology Drug Revenue by Manufacturer (2019-2024)
  • 3.3 Global Late-Stage Oncology Drug Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Late-Stage Oncology Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Late-Stage Oncology Drug Manufacturer Market Share in 2023
    • 3.4.3 Top 6 Late-Stage Oncology Drug Manufacturer Market Share in 2023
  • 3.5 Late-Stage Oncology Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Late-Stage Oncology Drug Market: Region Footprint
    • 3.5.2 Late-Stage Oncology Drug Market: Company Product Type Footprint
    • 3.5.3 Late-Stage Oncology Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Late-Stage Oncology Drug Market Size by Region
    • 4.1.1 Global Late-Stage Oncology Drug Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Late-Stage Oncology Drug Consumption Value by Region (2019-2030)
    • 4.1.3 Global Late-Stage Oncology Drug Average Price by Region (2019-2030)
  • 4.2 North America Late-Stage Oncology Drug Consumption Value (2019-2030)
  • 4.3 Europe Late-Stage Oncology Drug Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Late-Stage Oncology Drug Consumption Value (2019-2030)
  • 4.5 South America Late-Stage Oncology Drug Consumption Value (2019-2030)
  • 4.6 Middle East & Africa Late-Stage Oncology Drug Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 5.2 Global Late-Stage Oncology Drug Consumption Value by Type (2019-2030)
  • 5.3 Global Late-Stage Oncology Drug Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 6.2 Global Late-Stage Oncology Drug Consumption Value by Application (2019-2030)
  • 6.3 Global Late-Stage Oncology Drug Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 7.2 North America Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 7.3 North America Late-Stage Oncology Drug Market Size by Country
    • 7.3.1 North America Late-Stage Oncology Drug Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Late-Stage Oncology Drug Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 8.2 Europe Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 8.3 Europe Late-Stage Oncology Drug Market Size by Country
    • 8.3.1 Europe Late-Stage Oncology Drug Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Late-Stage Oncology Drug Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Late-Stage Oncology Drug Market Size by Region
    • 9.3.1 Asia-Pacific Late-Stage Oncology Drug Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Late-Stage Oncology Drug Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 10.2 South America Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 10.3 South America Late-Stage Oncology Drug Market Size by Country
    • 10.3.1 South America Late-Stage Oncology Drug Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Late-Stage Oncology Drug Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Late-Stage Oncology Drug Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Late-Stage Oncology Drug Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Late-Stage Oncology Drug Market Size by Country
    • 11.3.1 Middle East & Africa Late-Stage Oncology Drug Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Late-Stage Oncology Drug Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Late-Stage Oncology Drug Market Drivers
  • 12.2 Late-Stage Oncology Drug Market Restraints
  • 12.3 Late-Stage Oncology Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Late-Stage Oncology Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Late-Stage Oncology Drug
  • 13.3 Late-Stage Oncology Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Late-Stage Oncology Drug Typical Distributors
  • 14.3 Late-Stage Oncology Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    A late-stage oncology drug refers to a medication or treatment that has advanced through the initial phases of clinical trials (phases I and II) and is now being tested in phase III clinical trials or is awaiting regulatory approval for marketing. These drugs are typically intended for the treatment of cancer in patients who have advanced disease or have not responded well to standard treatments. Late-stage oncology drugs undergo rigorous testing to assess their safety, efficacy, and potential side effects in larger groups of patients before they can be approved for use in clinical practice.
    According to our (Global Info Research) latest study, the global Late-Stage Oncology Drug market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Late-Stage Oncology Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Late-Stage Oncology Drug market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2019-2030
    Global Late-Stage Oncology Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2019-2030
    Global Late-Stage Oncology Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2019-2030
    Global Late-Stage Oncology Drug market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/g), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Late-Stage Oncology Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Late-Stage Oncology Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Merck & Co, Bristol Myers, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Eli Lilly and Company, Sanofi, AbbVie, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Late-Stage Oncology Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Chemotherapy
    Targeted Therapy
    Immunotherapy
    Hormonal Therapy
    Others
    Market segment by Application
    Blood Cancer
    Breast Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Respiratory or Lung Cancer
    Other
    Major players covered
    Roche
    Merck & Co
    Bristol Myers
    Pfizer
    Novartis
    AstraZeneca
    Johnson & Johnson
    Eli Lilly and Company
    Sanofi
    AbbVie
    GSK
    Amgen
    Genentech
    Daiichi Sankyo Group
    Aveo Oncology
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Late-Stage Oncology Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Late-Stage Oncology Drug, with price, sales quantity, revenue, and global market share of Late-Stage Oncology Drug from 2019 to 2024.
    Chapter 3, the Late-Stage Oncology Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Late-Stage Oncology Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Late-Stage Oncology Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Late-Stage Oncology Drug.
    Chapter 14 and 15, to describe Late-Stage Oncology Drug sales channel, distributors, customers, research findings and conclusion.

    Buy now